Crewe Advisors’s Anika Therapeutics ANIK Stock Holding History

Crewe Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-82	Closed	-$3K	–	454
2020 Q3	$3K	Buy	+82	New	+$2.96K	﹤0.01%	428

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Crewe Advisors's ANIK Position: Q4 2020 in Review

Crewe Advisors sold out of Anika Therapeutics (ANIK) in Q4 2020, closing a stake of 82 shares — an estimated $3K sold.

Crewe Advisors first reported a position in ANIK in Q3 2020 and held it in 1 quarter. The position peaked at $3K in Q3 2020. 164 funds tracked by Wall St. Rank hold ANIK as of Q4 2020.

Crewe Advisors reported no remaining Anika Therapeutics position as of Q4 2020 after selling out during the quarter.
Crewe Advisors sold 82 Anika Therapeutics shares in Q4 2020, an estimated $3K.
Crewe Advisors first reported a position in Anika Therapeutics in Q3 2020 and held it in 1 quarter.
Crewe Advisors's Anika Therapeutics position peaked at $3K in Q3 2020.
164 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2020.

Based on Crewe Advisors's 13F filing for Q4 2020, filed 27 Jan 2021.